Grossi, Francesco

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 6,607

First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 1,215

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 733

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G., Brambilla, M., Baglivo, S., Grossi, F., & Chiari, R. (2019) · Journal of Cancer Research and Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 345

Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E. G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., Brighenti, M., et al. (2020) · Cancers

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 300

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

Salvi, S., Fontana, V., Boccardo, S., Merlo, D. F., Margallo, E., Laurent, S., Morabito, A., Rijavec, E., Dal Bello, M. G., Mora, M., et al. (2012) · Cancer Immunology Immunotherapy

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 133

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme

Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 111

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)

Grossi, F., Jaśkiewicz, P., Ferreira, M., Czyżewicz, G., Kowalski, D., Ciuffreda, L., Garcia-Gomez, R., Caruso, S., Bosch-Barrera, J., Gautier, S., et al. (2021) · Therapeutic Advances in Medical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5